DUBLIN – Biotech investors shrugged off short-term fears about any potential fallout from Thursday's looming vote on Britain's continued membership of the EU, pumping more than $125 million into two U.K. firms, Verona Pharma plc and F2G Ltd., which will enable them to move their respective drug candidates into a phase IIb trial in chronic obstructive pulmonary disease (COPD) and a registration study in invasive aspergillosis.